Neuroblastoma: Current drug therapy recommendations as part of the total treatment approach

Drugs

Volumn 59, Issue 6, 2000, Pages 1261-1277

  Berthold, Frank ^a,b   Hero, Barbara ^a  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^b UNIVERSITY OF COLOGNE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; ANTHRACYCLINE; ANTIINFECTIVE AGENT; BLEOMYCIN; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DACARBAZINE; DACTINOMYCIN; DNA TOPOISOMERASE INHIBITOR; DOXORUBICIN; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; HYDROXYUREA; IFOSFAMIDE; IRINOTECAN; MELPHALAN; MESNA; MITOXANTRONE; PLATINUM DERIVATIVE; RETINOIC ACID; TENIPOSIDE; THIOTEPA; TIOGUANINE; TOPOTECAN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINCRISTINE; VINDESINE; ZILASCORB;

ADJUVANT CHEMOTHERAPY; BONE MARROW DEPRESSION; CANCER INCIDENCE; CANCER RISK; CANCER SURVIVAL; CLINICAL TRIAL; DOSE RESPONSE; DRUG MECHANISM; GERMANY; HUMAN; MYELODYSPLASTIC SYNDROME; MYELOID LEUKEMIA; NEPHROTOXICITY; NEUROBLASTOMA; OTOTOXICITY; REVIEW; STEM CELL TRANSPLANTATION;

EID: 0034053718     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200059060-00006     Document Type: Review

References (56)

1. 1. Brodeur GM, Prichard J, Berthold F, et al. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol 1993; 11: 1466-77
2. 2. Ambros IM, Zellner A, Roald B, et al. Role of ploidy, chromosome 1p, and schwann cells in the maturation of neuroblastoma. N Engl J Med 1996; 334: 1505-11
3. 3. Kaatsch P, Kaletsch U, Spix C, et al. Annual report 1998, German Childhood Cancer Registry. Mainz: German Childhood Cancer Registry, 1999: 72, 88
4. 4. Powell JE, Estève J, Mann JR, et al. Neuroblastoma in Europe: differences in the pattern of disease in the UK. Lancet 1998; 352: 682-7
5. 5. Berthold F, Sahin K, Christiansen H, et al. The current contribution of molecular factors in risk estimation in neuroblastoma patients. Eur J Cancer 1997; 33: 2092-7
6. 6. Berthold F, Kassenböhmer R, Zischang J. Multivariate evaluation of prognostic factors in localized neuroblastoma. Am J Pediatr Hematol Oncol 1994; 16: 107-15
7. 7. Hero B, Hunneman DH, Gahr M, et al. Evaluation of catecholamine metabolites, mIBG scan and bone marrow cytology as response markers in stage 4 neuroblastoma. Med Pediatr Oncol. In press
8. 8. Seeger RC, Brodeur GM, Sather H, et al. Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas. N Engl J Med 1985; 313: 1111-6
9. 9. Bordow SB, Norris MD, Haber PS, et al. Prognostic significance of MYCN oncogene expression in childhood Neuroblastoma. J Clin Oncol 1998; 16: 3286-94
10. 10. Carlsen N, Ørnvold K, Christensen IJ, et al. Prognostic importance of DNA flow cytometrical, histopathological and immunohistochemical parameters in neuroblastomas. Virchows Arch A Pathol Anat Histopathol 1992; 420: 411-8
11. 11. Look AT, Hayes A, Shuster JJ, et al. Clinical relevance of tumor cell ploidy and N.myc gene amplification in childhood neuroblastoma: a pediatric oncology group study. J Clin Oncol 1991; 9: 581-91
12. 12. Christiansen H, Lampert F. Tumour karyotype discriminates between good and bad prognostic outcome in neuroblastoma. Br J Cancer 1988; 57: 121-6
13. 13. Caron H, van Sluis P, de Kraker J, et al. Allelic loss of chromosome 1p as a predictor of unfavorable outcome in patients with neuroblastoma. N Engl J Med 1996; 334: 225-30
14. 14. Gehring M, Berthold F, Edler L, et al. The 1p deletion is not a reliable marker for the prognosis of patients with neuroblastoma. Cancer Res 1995; 55: 5366-9
15. 15. Savelyeva L, Corvi R, Schwab M. Translocation involving 1p and 17q is a recurrent genetic alteration of human Neuroblastoma cells. Am J Hum Genet 1994; 55: 334-40
16. 16. Caron H. Allelic loss of chromosome 1 and additional chromosome 17 material are both unfavourable prognostic markers in neuroblastoma. Med Pediatr Oncol 1995; 24: 215-21
17. 17. Norris MD, Bordow SB, Marshall GM, et al. Expression of the gene for multidrug-resistance-associated protein and outcome in patients with neuroblastoma. N Engl J Med 1996; 334: 231-8
18. 18. Hiyama E, Hiyama K, Yokoyama T, et al. Correlating telomerase activity levels with human neuroblastoma outcomes. Nat Med 1995; 1: 249-55
19. 19. Maitra A, Yashima K, Rathi A, et al. The RNA component of telomerase as a marker of biologic potential and clinical outcome in childhood neuroblastic tumors. Cancer 1991; 85: 741-9
20. 20. Kogner P, Barbany G, Dominici C, et al. Coexpression of messenger RNA for TRK protooncogene and low affinity nerve growth factor receptor in Neuroblastoma with favorable prognosis. Cancer Res 1993; 53: 2044-50
21. 21. Nakagawara A, Arima-Nakagawara M, Scavarda N, et al. Association between high levels of expression of the TRK gene and favorable outcome in human neuroblastoma. N Engl J Med 1993; 328: 847-54
22. 22. Terpe HJ, Christiansen H, Berthold F, et al. Absence of CD44-standard in human neuroblastoma correlates with histological dedifferentiation, N-myc amplification and reduced survival probability. Cell Death Differ 1994; 1: 123-8
23. 23. Combaret V, Gross N, Lasset C, et al. Clinical relevance of CD44 cell surface expression and MYCN gene amplification in neuroblastoma. Eur J Cancer 1997; 33: 2101-5
24. 24. Berthold F, Hero B, Jobke A, et al. Sind Spontanregressionen beim Neuroblastom verspätete embryofetale Involutionen? In: Heim ME, Schwarz R, editors. Spontanremissionen bei krebserkrankungen. Stuttgart: Schattauer Verlag, 1998: 84-94
25. 25. Woods WG, Tuchman M, Robison LL, et al. A population-based study of the usefulness of screening for neuroblastoma. Lancet 1996; 348: 1682-7
26. 26. Prasad KN. Differentiation of neuroblastoma cells in culture. Biol Rev Camb Philos Soc 1975; 50: 129-65
27. 27. Fulda S, Honer M, Menke-Moellers I, et al. Antiproliferative potential of cytostatic drugs on neuroblastoma cells in vitro. Eur J Cancer 1995; 31A: 616-21
28. 28. Hartmann O, Berthold F. Treatment of advanced neuroblastoma: the european experience, In: Brodeur GM, Sawada T, Tsuchida Y, et al, editors. Neuroblastoma. Amsterdam: Elsevier Press, 2000: 436-52
29. 29. Tsuchida Y, Kaneko M. Treatment of advanced neuroblastoma: the Japanese experience, In: Brodeur GM, Sawada T, Tsuchida Y, et al., editors. Neuroblastoma. Amsterdam: Elsevier Press, 2000: 453-70
30. 30. Matthay KK, Castleberry RP. Treatment of advanced neuroblastoma: the U.S. experience. In: Brodeur GM, Sawada T, Tsuchida Y, et al., editors. Neuroblastoma. Amsterdam: Elsevier Press, 2000: 417-36
31. 31. Pritchard J, McElwain TJ, Graham-Pole J. High-dose melphalan with autologous marrow for treatment of advanced neuroblastoma. Br J Cancer 1982; 45: 86-94
32. 32. Matthay K, Villablanca JG, Seeger RC, et al. Treatment of high risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation and 13-cis-retmoic acid. N Engl J Med 1999; 341: 1165-73
33. 33. Hartmann O, Valteau-Couanet D, Benhamou E, et al. Stage IV neuroblastoma in patients over 1 year of age at diagnosis: consolidation of poor responders with combined busulfan, cyclophosphamide and melphalan followed by in vitro mafosfamide-purged autologous bone marrow transplantation. Eur J Cancer 1997; 33: 2126-9
34. 34. Philip T, Ladenstein R, Lasset C, et al. 1070 myeloablative megatherapy procedures followed by stem cell rescue for neuroblastoma: 17 years of european experience and conclusions. Eur J Cancer 1997; 33: 2130-5
35. 35. Keshelava N, Seeger RC, Groshen S, et al. Drug resistance patterns of human neuroblastoma cell lines derived from patients at different phases of therapy. Cancer Res 1998; 58: 5396-405
36. 36. Bates ES, Shieh CY, Tsokos M. Expression of mdr-1/P-glycoprotein in human neuroblastoma. Am J Pathol 1991; 139: 305-15
37. 37. Kurowski C, Berthold F. Presence of classical multidrug resistance and P-glycoprotein expression in human neuroblastoma cells. Ann Oncol 1998; 9: 1009-14
38. 38. Fulda S, Sieverts H, Friesen C, et al. The CD95 (APO-1/Fas) System mediates drug-induced apoptosis in neuroblastoma cells. Cancer Res 1997; 57: 3823-9
39. 39. Castleberry RP. Chemotherapy of neuroblastoma. In: Pochedly C, editor. Neuroblastoma: tumor biology and therapy. Boca Raton (FL): CRC Press Inc., 1998: 306-16
40. 40. Cheung N-K, Heller G. Chemotherapy dose intensity correlates strongly with response, median survival, and median progression-free survival in metastatic neuroblastoma. J Clin Oncol 1991; 9: 1050-8
41. 41. Frappaz D, Michon J, Coze C, et al. LMCE3 treatment strategy: results in 99 consecutively diagnosed stage 4 neuroblastomas in children older than 1 year at diagnosis. J Clin Oncol 2000; 18: 468-76
42. 42. Matthay K, Sather H, Seeger R, et al. Excellent outcome of stage II neuroblastoma is independent of residual disease and radiation therapy. J Clin Oncol 1989; 7: 236-44
43. 43. Evans A, Silber J, Shpilsky A, et al. Successful management of low-stage neuroblastoma without adjuvant therapies: a comparison of two decades, 1972 through 1981 and 1982 through 1992 in a single institution. J Clin Oncol 1997; 14: 2504-10
44. 44. Berthold F, Harms Diagnose, Lampert F, et al. Risk factors in neuroblastoma of infants, In: Huber H, Queisser W, editors. Contribution to oncology. Basel: S. Karger AG: 1990; 41: 101-17
45. 45. Berthold F. Neuroblastom. In: Schmoll H-J, Hoeffken K, Possinger K, editors. Kompendium internistische onkologie. Berlin: Springer, 1999: 2389-402
46. 46. Hoover M, Bowman L, Crawford SE, et al. Long-term outcome of patients with intraspinal neuroblastoma. Med Pediatr Oncol 1999; 32: 353-9
47. 47. Berthold F, Burdach S, Kremens B, et al. The role of chemotherapy in the treatment of children with neuroblastoma stage IV: the GPO (German Pediatric Oncology Society) experience. Klin Pädiatr 1990; 202: 262-9
48. 48. Kushner BH, Cheung N-K, Kramer K, et al. Neuroblastoma and treatment-related myelodysplasia/leukemia: the memorial Sloan-Kettering experience and a literature review. J Clin Oncol 1998; 16: 3880-9
49. 49. Handgretinger R, Greil J, Schurmann U, et al. Positive selection and transplantation of peripheral CD34+ progenitor cells: feasibility and purging efficacy in pediatric patients with neuroblastoma. J Hematother 1997; 6: 235-42
50. 50. Hafer R, Voigt A, Gruhn B, et al. Neuroblastoma cells can express the hematopoietic cell antigen CD34 as detected at surface protein an mRNA level. J Neuroimmunol 1999; 96: 201-6
51. 51. Kemshead JT, Heath L, Gibson FM, et al. Magnetic microspheres an monoclonal antibodies for the depletion of neuroblastoma cells from bone marrow: experiences, improvements and observations. Br J Cancer 1986; 54: 771-8
52. 52. Hero B, Niemeyer C, Dörffel W, et al. Increased incidence of secone leukemia after maintenance chemotherapy in neuroblastoma patients [abstract]. Med Pediatr Oncol 1996; 27: 303
53. 53. Michon JM, Hartmann O, Bouffet E, et al. An open-label, multicentre, randomised phase 2 study of recombinant human granulocyte colony-stimulating factor (filgrastim) as an adjunct to combination chemotherapy in paediatric patients with metastatic neuroblastoma. Eur J Cancer 1998; 34: 1063-9
54. 54. Timeus F, Crescenzio N, Valle P, et al. Stem cell factor suppresses apoptosis in neuroblastoma cell lines. Exp Hematol 1997; 25 : 1253-60
55. 55. Vassal G, Pinkerton R. Experimental therapeutics and new agents for neuroblastoma. In: Brodeur GM, Sawada T, Tsuchida Y, et al., editors. Neuroblastoma. Amsterdam: Elsevier Press, 2000: 383-92
56. 56. Saylors R, Stewart C, Zamboni W, et al. Phase I study of topotecan in combination with cyclophosphamide in pediatric patients with malignant solid tumor: a pediatric oncology group study. J Clin Oncol 1998; 16: 945-52